본문으로 건너뛰기
← 뒤로

Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

1/5 보강
European journal of cancer (Oxford, England : 1990) 📖 저널 OA 18.8% 2021: 0/1 OA 2022: 0/1 OA 2023: 0/2 OA 2024: 1/8 OA 2025: 2/74 OA 2026: 36/116 OA 2021~2026 2026 Vol.232() p. 116120
Retraction 확인
출처

Roos-Weil D, Tomowiak C, Poulain S, Nguyen-Khac F, Bouclet F, Armand M

📝 환자 설명용 한 줄

Waldenström's macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that predominantly affects older adults.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Roos-Weil D, Tomowiak C, et al. (2026). Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.. European journal of cancer (Oxford, England : 1990), 232, 116120. https://doi.org/10.1016/j.ejca.2025.116120
MLA Roos-Weil D, et al.. "Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.." European journal of cancer (Oxford, England : 1990), vol. 232, 2026, pp. 116120.
PMID 41349152 ↗

Abstract

Waldenström's macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that predominantly affects older adults. In recent years, significant progress has been made in understanding its pathogenesis, identifying relevant biomarkers, and developing novel therapeutic approaches to complement traditional chemoimmunotherapy-collectively reshaping the management landscape of WM. In this article, we provide comprehensive, evidence-based recommendations for the diagnosis, molecular evaluation, and treatment of WM, including strategies for both frontline and relapsed disease. These guidelines are informed by the latest clinical research, expert consensus, and current practice standards, with the goal of equipping clinicians with a practical and effective framework for delivering optimal care to patients with WM.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반